Nootropic Peptides: Semax, Selank and Cognitive Research
A sober overview of Semax, Selank, Semax-Selank Mix, PE-22-28 and Adamax. Focus on mechanisms, evidence base and research applications.
Peptide-based nootropic candidates are often described as their own class because they do not only address classical neurotransmitter systems. Depending on the compound, the discussed mechanisms range from neurotrophic signaling pathways through GABAergic modulation to the blockade of ion channels. That is precisely why a clean separation by mechanism is worthwhile rather than a blanket classification of all substances under "BDNF peptides."
The compounds covered here - Semax, Selank, the Semax + Selank Mix, PE-22-28, and Adamax - come from different research lineages. What they have in common above all is that they are investigated as substances for CNS-related research. The evidence base is, however, uneven: Semax and Selank are considerably more extensively described than PE-22-28 or Adamax.
What makes nootropic peptides different
Different target structures rather than one shared main pathway
A nootropic peptide is a short-chain amino acid sequence that can show cognitive, affective, or neuroprotective effects in research models. Russian research programs had clinically and regulatorily established Semax and Selank already in the 1990s; part of the literature often cited today comes from that context.
Important is the mechanistic differentiation: Semax is primarily associated with neurotrophic and monoaminergic effects, Selank more with GABA-A-related modulation and enkephalinase inhibition, while Spadin analogs like PE-22-28 are investigated through TREK-1 blockade. These substances therefore do not all activate the same "standard nootropic pathway."
Semax: Neurotrophic and monoaminergic effects
Semax is a synthetic heptapeptide based on the ACTH(4-10) fragment with a Pro-Gly-Pro extension at the C-terminus. It was developed in Russia and has been described there in medical applications since the 1990s; later status changes should not be confused with the original introduction.
What is plausibly established for Semax
For Semax there is preclinical and translationally oriented data on gene expression changes, neuroprotection, and modulation of monoaminergic systems. The literature also discusses an influence on BDNF- and partly NGF-related signaling pathways, but this should be read as preclinical evidence and not as a clinically established primary effect. Relevant works include PubMed PMID 16996037 and PMID 18756821.
In research settings, Semax has been investigated among other things in models for memory, ischemic damage, and attention-related parameters. Intranasal administration is common because it can enable direct nose-to-brain transport. A cautious formulation is appropriate here: intranasal application can facilitate entry into the CNS, but it does not blanket or completely "bypass" the blood-brain barrier. A good overview on this topic is offered by PubMed PMID 31126978.
Brain-boosting nootropic peptide derived from ACTH. Increases BDNF (brain-derived neurotrophic factor), enhances focus, memory, and mental clarity. Widely used in Russian clinical practice for cognitive enhancement.
Selank: GABAergic modulation and stress research
Selank is a synthetic Tuftsin analog with an additional Gly-Pro sequence. In the literature it is described primarily in the context of anxiety models, stress response, and neuroimmunological questions.
Mechanistically closer to GABA and enkephalins than to classical sedatives
The published data speak more for a modulating effect on GABA-A-related systems than for direct benzodiazepine-like agonism. Additionally, enkephalinase inhibition has been described for Selank. This supports the classification as an anxiolytically investigated peptide, but does not justify blanket statements like "without sedation, tolerance, or dependency risks." Relevant sources are PubMed PMID 11550013, PMID 26924987 and PMID 28293190.
Immunological effects are also discussed. For cytokines like IL-6, however, a narrow formulation is appropriate: the literature describes context-dependent changes in stress and immune models rather than a broadly established general core effect. Similarly, comparison with benzodiazepines should be limited to individual models and not read as direct clinical equivalence.
Synthetic tuftsin analog with anxiolytic, nootropic, and immunomodulatory properties. Developed at the Russian Academy of Sciences.
Semax + Selank: Why the combination is investigated
The Semax + Selank combination is often discussed in practice as a combination of cognitive and affective research focus. The underlying idea is understandable: Semax is more associated with plasticity and neuroprotection themes, Selank more with anxiety and stress models.
This combination logic is plausible, but should not be confused with hard combination evidence. Substantiable statements would be: the combination of both peptides simultaneously addresses two different hypotheses - cognitive performance parameters on the one hand and stress and tension parameters on the other. Statements about special prevalence, superior applicability, or sustained peak performance states are not necessary for this and are not cleanly supported by the available literature.
Useful as a hypothesis test, not a performance promise
For experimental designs, the combination can be interesting when both learning or attention markers and stress-related endpoints are to be captured. The quality of the conclusion then depends on clean operationalization, not on marketing terms like "stack."
Pre-mixed combination of the two leading nootropic peptides in one vial. Semax boosts focus and BDNF, Selank reduces anxiety and enhances calm. Together they provide balanced cognitive enhancement for research.
PE-22-28: TREK-1 as antidepressant research approach
PE-22-28 is a synthetic Spadin analog. Unlike Semax or Selank, the focus here is not neurotrophin signaling but the blockade of the two-pore potassium channel TREK-1. Precisely this blockade - not activation - is the mechanistic core.
Preclinical candidate focusing on TREK-1 blockade
In animal models, a rapid antidepressant-like effect has been described for Spadin and related candidates like PE-22-28. This includes changes in neuronal excitability and indications of downstream neurogenesis or BDNF-related processes. Nonetheless, it remains important: this literature is preclinical. Formulations like "works within days" or "completely bypasses the SSRI delay" go beyond what the evidence supports. A pertinent source for this research strand is PubMed PMID 28955242.
PE-22-28 is thus primarily an interesting tool candidate for research on alternative antidepressant mechanisms. The substance should not, however, be linguistically treated as if clinical efficacy data in humans already existed.
Adamax: Considerably thinner evidence base
Adamax is most often described as a structural Semax derivative with an adamantane group. From this, higher lipophilicity is often inferred. Further statements about clearly better brain penetration, longer half-life, or stronger BDNF response are, however, difficult to cleanly verify in easily accessible primary sources.
A cautious classification suffices for a substantiable representation: Adamax is a preclinically discussed derivative with a thinner evidence base than Semax. Those who work with it should view it more as an exploratory candidate than a demonstrably superior further development.
Choosing the right peptide for research
The selection should depend on the research question and the strength of the respective evidence.
Note on reconstitution
Intranasal peptides are delivered in lyophilized form. Reconstitute with bacteriostatic water before use.
References
- Ashmarin IP, Nezavibat'ko VN, et al. Semax-related neurochemical and neurotrophic data. PubMed PMID 16996037
- Semax and BDNF/TrkB-related preclinical discussion. PubMed PMID 18756821
- Selank and GABA/enkephalinase-related mechanisms. PubMed PMID 11550013
- Selank-related gene expression data with reference to GABAergic systems. PubMed PMID 26924987
- Selank-related gene expression data in another preclinical model. PubMed PMID 28293190
- Spadin or TREK-1-related preclinical research. PubMed PMID 28955242
- Nose-to-brain delivery and intranasal CNS application. PubMed PMID 31126978